Skip to content

Gland Pharma soars 5% on in-line Q2 results; should buy, hold or sell the stock?

Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies.

Read More

​ Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies. Gland Pharma earnings have bottomed out and are on track to recovery with stable pricing and volume-led growth across geographies, said Jefferies.  Moneycontrol Latest News Read More  

Leave a Reply

Your email address will not be published. Required fields are marked *

en_USEnglish